BACKGROUND: Complement activation via the MBL pathway has been proposed to play a role in the pathogenesis of diabetic complications. As protein glycation is increased in diabetes, we tested the possibility that the glycation product fructoselysine is a ligand for MBL and that its interaction with this protein may initiate complement activation. METHODS: We investigated the binding of MBL to fructoselysine by chromatography of human serum on fructoselysine-Sepharose, followed by Western blot and mass spectrometry analysis. We also performed enzyme-linked immunosorbent assays using purified MBL and fructoselysine-derivatized (binding assay) or mannan-coated plates (inhibition assay). Complement activation was determined by the fixation of C3d following incubation of fructoselysine-derivatized plates with serum from subjects with different levels of MBL. RESULTS: MBL and its associated proteases were selectively purified from serum by chromatography on fructoselysine-Sepharose. Competition experiments indicated that MBL had a similar affinity for mannose, fructose and fructoselysine. MBL bound, in a highly cooperative manner, to fructoselysine-derivatized plates. This binding was associated with complement activation and was much lower with serum from subjects with low-MBL genotypes. CONCLUSIONS: MBL binding to fructoselysine and the ensuing complement activation may provide a physiopathological link between enhanced glycation and complement activation in diabetes. The cooperative character of this binding may explain the high sensitivity of diabetic complications to hyperglycaemia.
BACKGROUND: Complement activation via the MBL pathway has been proposed to play a role in the pathogenesis of diabetic complications. As protein glycation is increased in diabetes, we tested the possibility that the glycation product fructoselysine is a ligand for MBL and that its interaction with this protein may initiate complement activation. METHODS: We investigated the binding of MBL to fructoselysine by chromatography of human serum on fructoselysine-Sepharose, followed by Western blot and mass spectrometry analysis. We also performed enzyme-linked immunosorbent assays using purified MBL and fructoselysine-derivatized (binding assay) or mannan-coated plates (inhibition assay). Complement activation was determined by the fixation of C3d following incubation of fructoselysine-derivatized plates with serum from subjects with different levels of MBL. RESULTS:MBL and its associated proteases were selectively purified from serum by chromatography on fructoselysine-Sepharose. Competition experiments indicated that MBL had a similar affinity for mannose, fructose and fructoselysine. MBL bound, in a highly cooperative manner, to fructoselysine-derivatized plates. This binding was associated with complement activation and was much lower with serum from subjects with low-MBL genotypes. CONCLUSIONS:MBL binding to fructoselysine and the ensuing complement activation may provide a physiopathological link between enhanced glycation and complement activation in diabetes. The cooperative character of this binding may explain the high sensitivity of diabetic complications to hyperglycaemia.
Authors: Vasile I Pavlov; Laura R La Bonte; William M Baldwin; Maciej M Markiewski; John D Lambris; Gregory L Stahl Journal: Am J Pathol Date: 2011-11-08 Impact factor: 4.307
Authors: Jakob A Østergaard; Steffen Thiel; Peter Hovind; Charlotte B Holt; Hans-Henrik Parving; Allan Flyvbjerg; Peter Rossing; Troels K Hansen Journal: Diabetologia Date: 2014-07-28 Impact factor: 10.122
Authors: S S Krogh; C B Holt; R Steffensen; K L Funck; P Høyem; E Laugesen; P L Poulsen; S Thiel; T K Hansen Journal: Clin Exp Immunol Date: 2017-04-20 Impact factor: 4.330
Authors: Christine von Toerne; Cornelia Huth; Tonia de Las Heras Gala; Florian Kronenberg; Christian Herder; Wolfgang Koenig; Christa Meisinger; Wolfgang Rathmann; Melanie Waldenberger; Michael Roden; Annette Peters; Barbara Thorand; Stefanie M Hauck Journal: Diabetologia Date: 2016-06-25 Impact factor: 10.122